HLA Matching and Crossmatching

HLA matching and crossmatching are the immunologic tests that establish whether a donor organ is compatible with a recipient. HLA typing characterizes the human leukocyte antigens of donor and recipient, while crossmatching detects whether the recipient already has antibodies against the donor that could trigger rejection. Together they guard against transplanting an organ the recipient's immune system is primed to attack.

Definition

HLA matching and crossmatching are the laboratory procedures that determine donor and recipient human leukocyte antigen types and detect preformed recipient antibodies against the donor, in order to assess immunologic compatibility before transplantation.

Scope

The topic covers human leukocyte antigen typing, the assessment of recipient sensitization and donor-specific antibodies, and the crossmatch tests used to detect preformed antibody before transplantation. It is a reference overview of compatibility testing and does not provide laboratory protocols or individualized clinical interpretation.

Core questions

• What are the donor's and recipient's HLA types, and how well do they match?
• Is the recipient sensitized, carrying antibodies against potential donors?
• Does the recipient have donor-specific antibodies that would jeopardize the graft?
• How does a positive crossmatch affect the decision to transplant?

Key concepts

• Human leukocyte antigens
• HLA typing and matching
• Sensitization and panel-reactive antibody
• Donor-specific antibodies
• Complement-dependent cytotoxicity crossmatch
• Flow cytometry and solid-phase antibody assays
• Antibody-mediated rejection

Mechanisms

Donor and recipient HLA molecules are identified, and the degree of mismatch between them is a determinant of the recipient's risk of mounting an immune response to the graft. Recipients exposed to foreign HLA through prior transplant, transfusion, or pregnancy may develop antibodies, and the crossmatch tests whether such antibodies bind the donor's cells. A positive crossmatch, indicating preformed donor-specific antibody, signals a high risk of immediate antibody-mediated injury, and contemporary solid-phase assays allow donor-specific antibodies to be characterized in detail. Persistent antibody-mediated injury is a leading cause of late graft loss.

Clinical relevance

Compatibility testing determines which donor-recipient pairings can proceed safely and which carry prohibitive immunologic risk, and it underlies strategies for transplanting sensitized patients. The entry describes how these tests function for reference purposes and is not a basis for individual laboratory interpretation or transplant decisions.

Epidemiology

Sensitized candidates, who carry antibodies against a broad range of potential donors, wait longer for a compatible organ, and donor-specific antibodies and antibody-mediated processes account for a substantial share of late graft failures, as observed in cohorts of failing kidney transplants.

Evidence & guidelines

Consensus guidance on HLA and non-HLA antibody testing and its clinical management is provided by Tait and colleagues (2013). The clinical importance of antibody-mediated injury in late graft loss is documented by Einecke and colleagues (2009), and the prognostic significance of a positive crossmatch was first established by Patel and Terasaki (1969).

History

The field began with the recognition that a positive lymphocyte crossmatch predicts hyperacute rejection, demonstrated by Patel and Terasaki in 1969, which made the complement-dependent cytotoxicity crossmatch standard practice. Increasingly sensitive flow-cytometric and solid-phase assays later allowed donor-specific antibodies to be detected and quantified, refining how immunologic risk is assessed and how sensitized patients are managed.

Debates

How should solid-phase antibody results guide transplant decisions?

Highly sensitive bead-based assays detect donor-specific antibodies that a cell-based crossmatch may miss, but the clinical significance of weakly positive results and the threshold for declining a donor remain subjects of debate.

Key figures

• Paul Terasaki
• Brian Tait
• Philip Halloran

Seminal works

• patel-terasaki-1969
• tait-2013
• einecke-2009

Frequently asked questions

What is the difference between HLA matching and crossmatching?

HLA matching compares the donor's and recipient's human leukocyte antigen types to gauge how well they correspond, whereas crossmatching tests whether the recipient already carries antibodies that would react against that specific donor.

Why does a positive crossmatch matter?

A positive crossmatch indicates that the recipient has preformed antibodies against the donor, which signals a high risk of rapid antibody-mediated rejection and traditionally contraindicates proceeding without special measures.